Drug Trial Radar · NCT04379050
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease
Last checked: Nov 19, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
130
Actual
Start
Jun 8, 2020
Primary completion
Apr 17, 2026
Study completion Apr 17, 2026
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- May 7, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. The purpose of this study is to continue testing whether ABBV-951 is safe, effective, and tolerable in participants with Parkinson's disease after completion of the parent study M15-741. ABBV-951 is an investigational (unapproved) drug containing levodopa phosphate/carbidopa phosphate (LDP/CDP) given as infusion under the skin for the treatment of Parkinson's Disease. Participants who have successfully completed M15-741 study will immediately enter this study's treatment period to continue receiving ABBV-951. Adult participants with advanced PD will be enrolled. Approximately 130 adult participants will be enrolled in the study at approximately 65 sites worldwide. Participants will receive continuous subcutaneous infusion (CSCI) of ABBV-951 for 24 hours daily during the Primary Treatment Period and during the optional Extended Treatment Period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular clinic visits and have remote assessments completed via phone calls during the course of the study. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects, and completing questionnaires.
Conditions
- Parkinson's Disease (PD)
Interventions
ABBV-951Drug
Solution for continuous subcutaneous infusion (CSCI).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Adverse Events (AE)Time frame: Up To Week 96
- Percentage Of Participants With Numeric Grade Equal To Or Higher Than 5 On The Infusion Site Evaluation ScaleTime frame: Up To Week 96
- Percentage Of Participants With Letter Grade Equal To Or Higher Than D On The Infusion Site Evaluation ScaleTime frame: Up To Week 96
- Change in Clinical Laboratory Test DataTime frame: Up To Week 96
- Change in Vital Signs MeasurementsTime frame: Up To Week 96
- Change From Baseline in Electrocardiograms (ECGs)Time frame: Up To Week 96
Locations
51 sites in 13 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham - Main /ID# 215597
Birmingham, Alabama
Banner Sun Health Research Institute /ID# 215579
Sun City, Arizona
University of Colorado Hospital /ID# 215625
Aurora, Colorado
Parkinson's Disease and Movement Disorders Center of Boca Raton /ID# 215412
Boca Raton, Florida
Indiana Clinical Research Cent /ID# 216490
Indianapolis, Indiana
Univ Kansas Med Ctr /ID# 215624
Kansas City, Kansas
Washington University-School of Medicine /ID# 215472
St Louis, Missouri
Dartmouth-Hitchcock Medical Center /ID# 216834
Lebanon, New Hampshire
M3 Wake Research - Raleigh /ID# 215596
Raleigh, North Carolina
Legacy Medical Group - Neurology /ID# 215536
Portland, Oregon
Baylor College of Medicine /ID# 215401
Houston, Texas
Central Texas Neurology Consul /ID# 217013
Round Rock, Texas
Univ Texas HSC San Antonio /ID# 215400
San Antonio, Texas
Booth Gardner Parkinson's Care Center /ID# 215535
Kirkland, Washington
Inland Northwest Research /ID# 215533
Spokane, Washington
Concord Repatriation General Hospital /ID# 215943
Concord, New South Wales, Australia
Westmead Hospital /ID# 215941
Westmead, New South Wales, Australia
Duplicate_Royal Adelaide Hospital /ID# 215940
Adelaide, South Australia, Australia
The Alfred Hospital /ID# 215942
Melbourne, Victoria, Australia
Perron Institute /ID# 215944
Nedlands, Western Australia, Australia
Duplicate_Groupe Sante CHC - Clinique du MontLegia /ID# 215685
Liège, Belgium
Universitair Ziekenhuis Leuven /ID# 215684
Leuven, Vlaams-Brabant, Belgium
Duplicate_Algemeen Ziekenhuis Sint-Jan Brugge /ID# 215686
Bruges, West-Vlaanderen, Belgium
University of Calgary /ID# 215369
Calgary, Alberta, Canada
Clinique Neuro Levis /ID# 215371
Lévis, Quebec, Canada
Bispebjerg and Frederiksberg Hospital /ID# 215391
Copenhagen NV, Capital Region, Denmark
Aarhus Universitetshospital - Skejby /ID# 215392
Aarhus, Central Jutland, Denmark
Odense University Hospital /ID# 215390
Odense, Region Syddanmark, Denmark
Kliniken Beelitz GmbH /ID# 215403
Beelitz-Heilstätten, Germany
Universitaetsklinikum Ulm /ID# 215405
Ulm, Baden-Wurttemberg, Germany
curiositas ad sanum /ID# 215404
Haag i.OB, Bavaria, Germany
IRCCS Centro Neurolesi Bonino Pulejo /ID# 215422
Messina, Italy
Azienda Ospedale-Universita Padova /ID# 215421
Padova, Italy
National Hospital Organization Asahikawa Medical Center /ID# 218762
Asahikawa-shi, Hokkaido, Japan
Duplicate_Osaka University Hospital /ID# 217415
Suita-shi, Osaka, Japan
National Center of Neurology and Psychiatry /ID# 218763
Kodaira-shi, Tokyo, Japan
St. Antonius Ziekenhuis, Locatie Utrecht /ID# 215396
Utrecht, Netherlands
Academician I.P. Pavlov First St. Petersburg State Medical University /ID# 218869
Saint Petersburg, Sankt-Peterburg, Russia
City Clinical Hospital #40 /ID# 218870
Sestroretsk, Sankt-Peterburg, Russia
Hospital Santa Creu i Sant Pau /ID# 215429
Barcelona, Spain
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.